Covid-19 roundup: CEPI pours $328M in­to Clover's vac­cine; For­mer Shkre­li com­pa­ny li­cens­es po­ten­tial treat­ment for $20M

Af­ter pour­ing $69.5 mil­lion in­to the de­vel­op­ment Clover Bio­phar­ma­ceu­ti­cals’ Covid-19 vac­cine, CEPI is back with an­oth­er $250 mil­lion-plus to fin­ish what it start­ed.

The lat­est …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.